Rational Vaccines, Inc. articles
ABSTRACT
Background: Although development of an HSV vaccine is a priority there is currently no vaccine available. The recent failure of subunit vaccines suggest that presentation of more antigens via a live attenuated vaccine may be required for protection. We therefore evaluated VC2. a live attenuated HSV vaccine, engineered to be unable to enter into neuronal axons.
Methods: VC2 pathogenesis was first evaluated in guinea pigs following intr
Abstract
Background
Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed.
Methods
A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses of intramuscular (IM) vaccine were provided followed by intra-vaginal challenge with HSV-2 at eit
Founder and CEO, Agustin Fernand of Rational Vaccines that is developing a vaccine for herpes.
There is a pandemic raging across the world – and it has nothing to do with a coronavirus. Approximately 500 million people worldwide suffer from genital herpes. Several billion more have an oral herpes infection. Herpes is a life-
Study to be conducted at two leading research institutions in the U.K.
Results will inform protocol design of Phase 1/2 clinical trial of Company`s lead HSV-2 therapeutic vaccine candidate
WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical
In the span of seven days, Mel Smith left her verbally abusive boyfriend, moved out of their house with her 13-year-old son, and found out that she had contracted genital herpes.
“I didn’t know what it was. I didn’t know what to do,” she says, remembering the time five years ago when her vagina itched so badly she couldn’t wear underwear. Her diagnosis? Herpes simplex virus.